Anti-CCR5 antibodies to the chemokine or to the HIV binding site, i.e. recognizing the N-terminus and/or the ECL2 domain, usually appear in response to experimental immunization with cells expressing CCR5 or to HIV infection; these antibodies block HIV entry by binding competition or steric hindrance [16,36]. This evidence concerns the gene CCR5 and HIV infectious disease.